Medications, label and off-label. Honest context.

Off-label is not unregulated. A drug is FDA-approved for specific indications, but a licensed physician can prescribe it for any condition where the evidence and risk-benefit ratio support it. That's how longevity medicine works in practice — metformin for healthspan, rapamycin for cellular aging, low-dose naltrexone for inflammation, GLP-1s for cardiometabolic risk outside diabetes. Approved use is the floor, not the ceiling.

Evidence grades are not equal. A randomized controlled trial outranks a cohort study, which outranks case reports, which outrank mechanism plus optimism. We mark each medication's off-label evidence A (multiple RCTs), B (one RCT or strong observational), C (mechanistic plus case series), or D (animal or theoretical). Read the grade before you read the dosing.

Interactions and monitoring matter. Statins plus grapefruit. Metformin plus contrast dye. SGLT2 inhibitors plus dehydration. Rapamycin plus immune suppression. Every profile lists known drug-drug interactions, the labs to monitor (LFTs, CMP, lipids, HbA1c, cortisol), and the cadence. Off-label does not mean unmonitored — it means more careful, not less.

This is educational, not prescriptive. Nothing on these pages is medical advice. No page tells you to start, change, or stop a medication. Bring the evidence to your physician, discuss risk-benefit in your specific context, and decide together. If a doctor refuses to engage with the literature, find one who will — but don't self-prescribe based on a website.